Itraconazole

Matching articles for "Itraconazole"

Treatment of Onychomycosis

The Medical Letter on Drugs and Therapeutics • October 18, 2021; (Issue 1635)

Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include...

Onychomycosis is caused most commonly by Trichophyton rubrum or T. mentagrophytes. About 10% of all persons worldwide and 40% of those ≥60 years old are believed to have the disease. Risk factors include older age, diabetes, poor peripheral circulation, smoking, HIV infection, psoriasis, and immunosuppression. Left untreated, onychomycosis can cause nail plate destruction, ingrown nails, and (particularly in patients with diabetes) secondary infections. Guidelines on treatment of onychomycosis have been published.

Med Lett Drugs Ther. 2021 Oct 18;63(1635):164-8 | Show Full Introduction Hide Full Introduction

Drugs for Helicobacter pylori Infection

The Medical Letter on Drugs and Therapeutics • July 17, 2017; (Issue 1525)

About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease,...

About 50% of the world’s population is infected with Helicobacter pylori. These gastric bacteria can cause chronic inflammation and have been associated with development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori can promote gastric healing, prevent recurrence of duodenal and gastric ulcers, and reduce the incidence of gastric cancer. Guidelines for treatment of H. pylori infection were updated recently.

Med Lett Drugs Ther. 2017 Jul 17;59(1525):113-7 | Show Full Introduction Hide Full Introduction

Drugs for Sexually Transmitted Infections

The Medical Letter on Drugs and Therapeutics • July 3, 2017; (Issue 1524)

The text and tables that follow include recommendations for management of sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have...

Med Lett Drugs Ther. 2017 Jul 3;59(1524):105-12 | Show Full Introduction Hide Full Introduction

Tavaborole Topical Solution (Kerydin) for Onychomycosis

The Medical Letter on Drugs and Therapeutics • March 2, 2015; (Issue 1463)

The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first...

The FDA has approved tavaborole 5% solution (Kerydin – Anacor Pharmaceuticals) for topical treatment of toenail onychomycosis due to Trichophyton rubrum or Trichophyton mentagrophytes. It is the first oxaborole antifungal drug to be approved for this indication.

Med Lett Drugs Ther. 2015 Mar 2;57(1463):35 | Show Full Introduction Hide Full Introduction

Efinaconazole Topical Solution (Jublia) for Onychomycosis

The Medical Letter on Drugs and Therapeutics • September 15, 2014; (Issue 1451)

The FDA has approved efinaconazole 10% solution (Jublia – Valeant) for topical treatment of toenail onychomycosis due to Trichophyton rubrum and/or Trichophyton mentagrophytes. It is the first...

The FDA has approved efinaconazole 10% solution (Jublia – Valeant) for topical treatment of toenail onychomycosis due to Trichophyton rubrum and/or Trichophyton mentagrophytes. It is the first topical triazole antifungal drug to be approved for this indication. A topical oxaborole antifungal solution, tavaborole 5% (Kerydin – Anacor), also recently approved by the FDA for the same indication will be reviewed in a future issue.

Med Lett Drugs Ther. 2014 Sep 15;56(1451):88-9 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • August 1, 2012; (Issue 120)

The drugs of choice for treatment of fungal infections are listed in the table that begins on page 62. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines for some of these infections are available online from the Infectious Diseases Society of America (www.idsociety.org).

Treat Guidel Med Lett. 2012 Aug;10(120):61-8 | Show Full Introduction Hide Full Introduction

New Simvastatin Dosing Recommendations

The Medical Letter on Drugs and Therapeutics • August 8, 2011; (Issue 1370)

The FDA has announced changes in the labeling of simvastatin to reduce the risk of myopathy. These changes include limiting the use of the 80-mg maximum dose to patients who have been taking it for 12 months or more without evidence of myopathy and new recommendations for use of simvastatin with other drugs. Simvastatin is available alone (Zocor, and others) and in combination with ezetimibe (Vytorin) and with niacin (Simcor).

Med Lett Drugs Ther. 2011 Aug 8;53(1370):61-2 | Show Full Introduction Hide Full Introduction

Drugs for Migraine

The Medical Letter on Drugs and Therapeutics • February 1, 2011; (Issue 102)

Drugs for treatment of migraine are listed in Table 2 on page 9. Drugs for prevention of migraine are listed in Table 3 on page 10. Treatment of migraine in the emergency room, which may involve use of...

Treat Guidel Med Lett. 2011 Feb;9(102):7-12 | Show Full Introduction Hide Full Introduction

Everolimus and Pazopanib: Two New Drugs for Renal Cell Cancer

The Medical Letter on Drugs and Therapeutics • May 3, 2010; (Issue 1337)

Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent)...

Everolimus (Afinitor – Novartis) and pazopanib (Votrient – GlaxoSmithKline), two oral multikinase inhibitors, have been approved by the FDA for treatment of advanced renal cell carcinoma. Sunitinib (Sutent) and sorafenib (Nexavar), two other oral multikinase inhibitors, and temsirolimus (Torisel), an IV multikinase inhibitor, were approved earlier for the same indication.

Med Lett Drugs Ther. 2010 May 3;52(1337):33-4 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • December 1, 2009; (Issue 88)

The drugs of choice for treatment of some fungal infections are listed. Some of the indications and dosages recommended here have not been approved by the FDA. More detailed guidelines are available online from...

Treat Guidel Med Lett. 2009 Dec;7(88):95-102 | Show Full Introduction Hide Full Introduction

Tolvaptan (Samsca) for Hyponatremia

The Medical Letter on Drugs and Therapeutics • November 30, 2009; (Issue 1326)

The FDA has approved the marketing of tolvaptan (Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF),...

The FDA has approved the marketing of tolvaptan (Samsca - Otsuka), an oral vasopressin receptor antagonist, for treatment of hypervolemic or euvolemic hyponatremia due to congestive heart failure (CHF), cirrhosis or the syndrome of inappropriate antidiuretic hormone secretion (SIADH). A similar drug, conivaptan (Vaprisol) is already available for intravenous (IV) treatment of euvolemic hyponatremia in hospitalized patients. Tolvaptan was approved by the FDA for both inpatient and outpatient use, but it should be started in a hospital.

Med Lett Drugs Ther. 2009 Nov 30;51(1326):95-6 | Show Full Introduction Hide Full Introduction

Fesoterodine (Toviaz) for Overactive Bladder

The Medical Letter on Drugs and Therapeutics • May 4, 2009; (Issue 1311)

The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this...

The FDA has approved the marketing of fesoterodine (Toviaz - Pfizer), a muscarinic receptor antagonist, for treatment of overactive bladder. It is the sixth antimuscarinic drug approved for this indication.

Med Lett Drugs Ther. 2009 May 4;51(1311):34-5 | Show Full Introduction Hide Full Introduction

Drug Interactions with Simvastatin

The Medical Letter on Drugs and Therapeutics • October 20, 2008; (Issue 1297)

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became...

A recent letter to the editor of the Annals of Internal Medicine documented a single case of myopathy apparently due to an interaction between simvastatin (Zocor, and others) and green tea. Since it became available generically, simvastatin has surpassed atorvastatin (Lipitor) as the best selling statin. As such, it is probably the most common cause of statin-induced myopathy, which is often a result of drug interactions.

Med Lett Drugs Ther. 2008 Oct 20;50(1297):83-4 | Show Full Introduction Hide Full Introduction

Treatment of Peptic Ulcers and GERD

The Medical Letter on Drugs and Therapeutics • August 1, 2008; (Issue 72)

Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. Most duodenal and other gastric ulcers are caused by the gram-negative bacillus Helicobacter pylori. Gastroesophageal reflux disease (GERD) is caused by gastric acid reflux into the esophagus. Drugs that suppress gastric acid production are the primary treatment for GERD and peptic ulcers.

Treat Guidel Med Lett. 2008 Aug;6(72):55-60 | Show Full Introduction Hide Full Introduction

Which Statin?

The Medical Letter on Drugs and Therapeutics • April 21, 2008; (Issue 1284)

Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much...

Advertisements for atorvastatin (Lipitor), the market leader facing generic competition, have been in the news recently in the US. Lovastatin, pravastatin and simvastatin are all available generically at a much lower retail price or lower co-pay than atorvastatin.

Med Lett Drugs Ther. 2008 Apr 21;50(1284):29-31 | Show Full Introduction Hide Full Introduction

Drugs for Lipids

The Medical Letter on Drugs and Therapeutics • February 1, 2008; (Issue 66)

Drugs that lower low-density lipoprotein cholesterol (LDL-C) concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions. They should not be used as a substitute for lifestyle changes; a combination of diet, exercise and lipid-lowering drugs is optimal for prevention of coronary disease. Lipid-regulating drugs must be taken indefinitely; when they are stopped, plasma lipoprotein levels return to pretreatment levels in 2-3 weeks.

Treat Guidel Med Lett. 2008 Feb;6(66):9-16 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • January 1, 2008; (Issue 65)

The drugs of choice for treatment of some fungal infections are listed in the tables. Some of the indications and dosages recommended here have not been approved by the FDA. Other guidelines are available from...

Treat Guidel Med Lett. 2008 Jan;6(65):1-8 | Show Full Introduction Hide Full Introduction

Posaconazole (Noxafil) for Invasive Fungal Infections

The Medical Letter on Drugs and Therapeutics • November 20, 2006; (Issue 1248)

Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus...

Posaconazole (Noxafil - Schering-Plough), an oral azole antifungal with a chemical structure similar to that of itraconazole (Sporanox), has been approved by the FDA to prevent Candida and Aspergillus infections in severely immunocompromised patients and for treatment of oropharyngeal candidiasis. It is likely also to be used off-label for treatment of other fungal infections, including those caused by Mucor and other Zygomycetes.

Med Lett Drugs Ther. 2006 Nov 20;48(1248):93-5 | Show Full Introduction Hide Full Introduction

CYP3A and Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 4, 2005; (Issue 1212)

Serious adverse interactions between drugs continue to be reported. Many of these are due to inhibition or induction of cytochrome P450 (CYP) enzymes, particularly CYP3A4. CYP3A is thought to be involved in the metabolism of more than 50 percent of currently prescribed drugs.2 CYP3A4, which is more abundantly expressed than CYP3A5, accounts for most CYP3A activity in vivo.

Med Lett Drugs Ther. 2005 Jul 4;47(1212):54-5 | Show Full Introduction Hide Full Introduction

Micafungin (Mycamine) for Fungal Infections

The Medical Letter on Drugs and Therapeutics • June 20, 2005; (Issue 1211)

Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation (HSCT).

Med Lett Drugs Ther. 2005 Jun 20;47(1211):51-2 | Show Full Introduction Hide Full Introduction

Erlotinib (Tarceva) for Advanced Non-Small Cell Lung Cancer

The Medical Letter on Drugs and Therapeutics • March 28, 2005; (Issue 1205)

Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a...

Erlotinib (Tarceva) is the second oral epidermal growth factor receptor (EGFR) inhibitor to become available in the US for treatment of advanced refractory NSCLC. In clinical trials, erlotinib produced a response rate of only 8.9%, but increased median survival from 4.7 to 6.7 months. Patients who had never smoked and those with EGFR-positive tumors survived longer. Erlotinib is generally well tolerated; diarrhea and rash are the most common adverse effects.

Med Lett Drugs Ther. 2005 Mar 28;47(1205):25-6 | Show Full Introduction Hide Full Introduction

Extended-Release Carbamazepine (Equetro) for Bipolar Disorder

The Medical Letter on Drugs and Therapeutics • March 28, 2005; (Issue 1205)

An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder....

An extended-release formulation of carbamazepine, available since 1997 for treatment of epilepsy, has now been approved under a new name, Equetro, for acute mania and mixed episodes of bipolar disorder. Although the drug was effective in some patients for up to 6 months, it has not been approved for maintenance treatment. Carbamazepine has not been shown to be more effective than lithium or valproate, and it can cause serious adverse effects.

Med Lett Drugs Ther. 2005 Mar 28;47(1205):27-8 | Show Full Introduction Hide Full Introduction

Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • February 1, 2005; (Issue 30)

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of some fungal infections are listed in the table that begins on page 8. Some of the indications and dosages recommended here have not been approved by the FDA.

Treat Guidel Med Lett. 2005 Feb;3(30):7-14 | Show Full Introduction Hide Full Introduction

Alprazolam (Xanax, and others) Revisited

The Medical Letter on Drugs and Therapeutics • January 17, 2005; (Issue 1200)

Alprazolam, a short-acting benzodiazepine, is one of the most widely prescribed drugs in the US. It is approved by the FDA for treatment of anxiety and panic disorder. An extended-release formulation, Xanax XR,...

Med Lett Drugs Ther. 2005 Jan 17;47(1200):5-7 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • December 1, 2004; (Issue 28)

Tuberculosis (TB) is still a problem in the United States, even though the incidence continues to decline in most of the country (MMWR Morbid Mortal Wkly Rep 2004; 53:209). Treatment of TB can be divided into treatment of latent infection diagnosed by a positive PPD and treatment of active clinical TB. Guidelines with detailed management recommendations are available from the US Centers for Disease Control and Prevention (CDC) (MMWR Morbid Mortal Wkly Rep 2003; 52RR-11:1).

Treat Guidel Med Lett. 2004 Dec;2(28):83-2 | Show Full Introduction Hide Full Introduction

Safety of Aggressive Statin Therapy

The Medical Letter on Drugs and Therapeutics • November 22, 2004; (Issue 1196)

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from...

New guidelines from The National Cholesterol Education Program recommend, as a therapeutic option, lowering treatment goals for LDL cholesterol (LDL-C) from <100 mg/dL to <70 mg/dL for patients at very high risk for coronary heart disease and from 130 mg/dL to <100 mg/dL for those at moderately high risk. A likely consequence of these recommendations is increased use of statins and use of higher doses with a concomitant increase in adverse effects.

Med Lett Drugs Ther. 2004 Nov 22;46(1196):93-5 | Show Full Introduction Hide Full Introduction

Drugs for Migraine

The Medical Letter on Drugs and Therapeutics • September 1, 2004; (Issue 25)

Drugs for treatment of migraine attacks are listed in the table on page 64. All of the oral drugs are most effective if taken early in an attack when the pain is mild (H Christoph-Diener et al, Neurology 2004; 63:520). Drugs for prevention of migraine are listed in the table on page 65. Treatment of migraine in the emergency room, which may involve use of intravenous drugs, is not included here.

Treat Guidel Med Lett. 2004 Sep;2(25):63-6 | Show Full Introduction Hide Full Introduction

Telithromycin (Ketek) for Respiratory Infections

The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)

Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in...

Telithromycin (Ketek - Aventis) has been approved by the FDA for oral treatment of mild to moderate community-acquired pneumonia, acute exacerbations of chronic bronchitis and acute bacterial sinusitis in patients age 18 and older. The drug is the first in a new class of antibiotics, the ketolides, derived from the macrolide erythromycin. Telithromycin has been marketed in Europe since 2001.

Med Lett Drugs Ther. 2004 Aug 16;46(1189):66-8 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • August 16, 2004; (Issue 1189)

Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table below lists first-choice and alternative drugs for most parasitic infections. The brand names and manufacturers of the drugs are listed in this article.

Med Lett Drugs Ther. 2004 Aug 16;46(1189):66 | Show Full Introduction Hide Full Introduction

Drugs for Peptic Ulcers

The Medical Letter on Drugs and Therapeutics • February 1, 2004; (Issue 18)

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related...

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related ulcers are gastric. H. pylori infection causes both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (A Shiotamni and DY Graham, Med Clin North Am 2002; 86:1447; FKL Chan and WK Leung, Lancet 2002; 360:933). The first step in the management of peptic ulcers is the diagnosis and treatment of H. pylori.

Treat Guidel Med Lett. 2004 Feb;2(18):7-12 | Show Full Introduction Hide Full Introduction

Drug Interactions with Grapefruit Juice

The Medical Letter on Drugs and Therapeutics • January 5, 2004; (Issue 1173)

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice...

The ability of grapefruit juice to increase serum concentrations of drugs was first discovered during a study of the effect of ethanol on felodipine (Plendil) pharmacokinetics. Double-strength grapefruit juice used to disguise the taste of ethanol resulted in higher than expected serum concentrations of felodipine (DG Bailey et al, Clin Invest Med 1989; 12:357).

Med Lett Drugs Ther. 2004 Jan 5;46(1173):2-4 | Show Full Introduction Hide Full Introduction

Alfuzosin (Uroxatral) -- Another Alpha1-blocker for Benign Prostatic Hyperplasia

The Medical Letter on Drugs and Therapeutics • January 5, 2004; (Issue 1173)

Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since...

Alfuzosin hydrochloride (Uroxatral - Sanofi-Synthelabo) is now available in the US in a new formulation for once-daily treatment of benign prostatic hyperplasia (BPH). The drug has been used in Europe since 1987. Alpha₁-blockers cause relaxation of smooth muscle tone in the bladder neck, prostatic capsule and prostatic urethra, relieving symptoms of urinary obstruction.

Med Lett Drugs Ther. 2004 Jan 5;46(1173):1-2 | Show Full Introduction Hide Full Introduction

Tadalafil (Cialis) for Erectile Dysfunction

The Medical Letter on Drugs and Therapeutics • December 22, 2003; (Issue 1172)

Tadalafil (Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil (Viagra) or vardenafil (Levitra -...

Tadalafil (Cialis - Lilly Icos) is the third oral drug to be approved by the FDA for treatment of erectile dysfunction. It has a longer duration of action than sildenafil (Viagra) or vardenafil (Levitra - Medical Letter 2003; 45:77).

Med Lett Drugs Ther. 2003 Dec 22;45(1172):101-2 | Show Full Introduction Hide Full Introduction

Vardenafil (Levitra) for Erectile Dysfunction

The Medical Letter on Drugs and Therapeutics • September 29, 2003; (Issue 1166)

Vardenafil (Levitra -Bayer) is the second oral drug approved by the FDA for treatment of erectile dysfunction. Sildenafil (Viagra - Medical Letter 1998; 40:51), the first oral drug, has been available for 5 years. Pharmacokinetics, effectiveness, adverse effects, dosage and cost of the new drug are reviewed. Whether it offers any benefits over sildenafil is discussed.

Med Lett Drugs Ther. 2003 Sep 29;45(1166):77-8 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • June 8, 2003; (Issue 1158)

Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.

Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 | Show Full Introduction Hide Full Introduction

Xanax XR for Panic Disorder

The Medical Letter on Drugs and Therapeutics • May 26, 2003; (Issue 1157)

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to...

The FDA has approved an extended-release (XR) formulation of the benzodiazepine alprazolam (Xanax XR - Pfizer) for treatment of panic disorder, with or without agoraphobia. The new formulation is intended to reduce the need for frequent dosing and problems of interdose anxiety. This review describes the effectiveness of the extended-release formulation, as well as sections on dependence, abuse and withdrawal, adverse effects, and drug interactions. The review concludes with an overall assessment of the drug's efficacy and cost.

Med Lett Drugs Ther. 2003 May 26;45(1157):43-4 | Show Full Introduction Hide Full Introduction

Eplerenone (Inspra)

The Medical Letter on Drugs and Therapeutics • May 12, 2003; (Issue 1156)

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of...

Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.

Med Lett Drugs Ther. 2003 May 12;45(1156):39-40 | Show Full Introduction Hide Full Introduction

Eletriptan (Relpax) for Migraine

The Medical Letter on Drugs and Therapeutics • April 28, 2003; (Issue 1155)

Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT1B/1D-receptor agonist (triptan) to be approved by the FDA...

Eletriptan hydrobromide (Relpax Pfizer) is now available in the US for oral treatment of migraine headache in adults. It is the seventh serotonin 5-HT_1B/1D-receptor agonist (triptan) to be approved by the FDA for this indication. This review describes the pharmacokinetics, adverse effects, drug interactions and recommended dosage of eletriptan. Clinical trials comparing the new drug to placebo and to sumatriptan are presented. A dosage and cost table for all the triptans available in the US is also included. The review concludes with an overall assessment of eletriptan's efficacy and safety.

Med Lett Drugs Ther. 2003 Apr 28;45(1155):33-4 | Show Full Introduction Hide Full Introduction

Aripiprazole (Abilify) for Schizophrenia

The Medical Letter on Drugs and Therapeutics • February 17, 2003; (Issue 1150)

Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of...

Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.

Med Lett Drugs Ther. 2003 Feb 17;45(1150):15-6 | Show Full Introduction Hide Full Introduction

Voriconazole

The Medical Letter on Drugs and Therapeutics • July 22, 2002; (Issue 1135)

Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary...

Voriconazole (Vfend -- Pfizer), an antifungal triazole structurally related to fluconazole (Diflucan) with a spectrum of action similar to that of itraconazole, has been approved by the FDA for primary treatment of invasive aspergillosis and for refractory infection with Scedosporium apiospermum (the asexual form of Pseudallescheria boydii) or Fusarium spp.

Med Lett Drugs Ther. 2002 Jul 22;44(1135):63-5 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • April 1, 2002; (Issue 1127)

Superseded--purchase updated Parasitic Infections article
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites.

Note: Drugs for Parasitic Infections, revised and updated, is now available to both subscribers and nonsubscribers on our web site. This article, a bi-annual feature of The Medical Letter for many years, will not be published as a printed issue in 2002, but is included in the 16th edition of The Medical Letter Handbook of Antimicrobial Therapy. The handbook is now available and can be ordered by calling customer service at 1-800-211-2769.

Med Lett Drugs Ther. 2002 Apr 1;44(1127):32 | Show Full Introduction Hide Full Introduction

Caspofungin (Cancidas) For Aspergillosis

The Medical Letter on Drugs and Therapeutics • July 9, 2001; (Issue 1108)

Caspofungin acetate(Cancidas) is the first of a new class of antifungals, the echinocandins. It has been approved by the FDA for treatment of invasive aspergillosis in patients who fail to respond to or are...

Med Lett Drugs Ther. 2001 Jul 9;43(1108):58-9 | Show Full Introduction Hide Full Introduction

Gleevec (STI-571) For Chronic Myeloid Leukemia

The Medical Letter on Drugs and Therapeutics • June 11, 2001; (Issue 1106)

Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon...

Imatinib mesylate (STI-571; Gleevec - Novartis), an oral tyrosine kinase inhibitor, has received accelerated approval from the FDA for treatment of all phases of chronic myeloid leukemia (CML) after interferon has failed.

Med Lett Drugs Ther. 2001 Jun 11;43(1106):49-50 | Show Full Introduction Hide Full Introduction

Ciclopirox (Penlac) Nail Lacquer for Onychomycosis

The Medical Letter on Drugs and Therapeutics • June 12, 2000; (Issue 1080)

Ciclopirox nail lacquer (Penlac - Dermik) has been approved by the FDA for treatment of mild-to-moderate onychomycosis due to Trichophyton rubrum, without involvement of the lunula. The drug has been available...

Ciclopirox nail lacquer (Penlac - Dermik) has been approved by the FDA for treatment of mild-to-moderate onychomycosis due to Trichophyton rubrum, without involvement of the lunula. The drug has been available for many years as a lotion and cream (Loprox) for treatment of cutaneous fungal infection

Med Lett Drugs Ther. 2000 Jun 12;42(1080):51-2 | Show Full Introduction Hide Full Introduction

Drug Interactions

The Medical Letter on Drugs and Therapeutics • July 2, 1999; (Issue 1056)

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new...

Reports of adverse interactions between drugs continue to accumulate. Recently, the FDA has expanded the recommendations on drug interactions found in the package inserts of new drugs.

Med Lett Drugs Ther. 1999 Jul 2;41(1056):59-62 | Show Full Introduction Hide Full Introduction

Cilostazol for Intermittent Claudication

The Medical Letter on Drugs and Therapeutics • May 7, 1999; (Issue 1052)

Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial...

Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.

Med Lett Drugs Ther. 1999 May 7;41(1052):44-6 | Show Full Introduction Hide Full Introduction

Sildenafil: An Oral Drug for Impotence

The Medical Letter on Drugs and Therapeutics • May 8, 1998; (Issue 1026)

Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus...

Sildenafil citrate (Viagra - Pfizer) is the first oral drug approved by the FDA for treatment of erectile dysfunction. Alprostadil is also marketed for this indication but must be injected into the corpus cavemosum (Caverject) or pushed into the urethra (MUSE).

Med Lett Drugs Ther. 1998 May 8;40(1026):51-2 | Show Full Introduction Hide Full Introduction

Drugs for Parasitic Infections

The Medical Letter on Drugs and Therapeutics • January 2, 1998; (Issue 1017)

(Superseded by the 2013 version. Click here to purchase.)
Parasitic infections are found throughout the world. With increasing travel, immigration, use of immunosuppressive drugs and the spread of AIDS, physicians anywhere may see infections caused by previously unfamiliar parasites. The table lists first-choice and alternative drugs for most parasitic infections.

Med Lett Drugs Ther. 1998 Jan 2;40(1017):1-12 | Show Full Introduction Hide Full Introduction

Systemic Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • September 12, 1997; (Issue 1009)

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the...

The drugs of choice for treatment of deep fungal infections are listed in the table below. Some of the indications and dosages recommended here have not been approved by the FDA.

Med Lett Drugs Ther. 1997 Sep 12;39(1009):86-8 | Show Full Introduction Hide Full Introduction

Atorvastatin - A New Lipid-lowering Drug

The Medical Letter on Drugs and Therapeutics • March 28, 1997; (Issue 997)

Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed...

Atorvastatin (Lipitor - Parke-Davis), an HMG-CoA reductase inhibitor (or 'statin'), was recently approved by the US Food and Drug Administration for treatment of primary hypercholesterolemia and mixed dyslipidemia. A single stereoisomer of a pyrrole derivative, the new drug is chemically different from other statins.

Med Lett Drugs Ther. 1997 Mar 28;39(997):29-31 | Show Full Introduction Hide Full Introduction

Drugs for Treatment of Peptic Ulcers

The Medical Letter on Drugs and Therapeutics • January 3, 1997; (Issue 991)

Most peptic ulcers not caused by nonsteroidal anti-inflammatory drugs (NSAIDs) are now thought to be associated with infection of the gastric mucosa by the gram-negative bacilli Helicobacter pylori. The majority of NSAID-related ulcers are gastric. H. pylori have been associated with both duodenal and gastric ulcers. Eradication of H. pylori promotes healing and markedly decreases recurrence of both duodenal and gastric ulcers (AH Soll, JAMA, 275:622, 1996).

Med Lett Drugs Ther. 1997 Jan 3;39(991):1-4 | Show Full Introduction Hide Full Introduction

Fexofenadine

The Medical Letter on Drugs and Therapeutics • October 25, 1996; (Issue 986)

Fexofenadine (fex oh fen' a deen) hydrochloride (Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of...

Fexofenadine (fex oh fen' a deen) hydrochloride (Allegra - Hoechst Marion Roussel) has been approved by the US Food and Drug Administration for treatment of seasonal allergic rhinitis. An active metabolite of terfenadine, fexofenadine is being heavily advertised as "nonsedating...without 'black box' warnings."

Med Lett Drugs Ther. 1996 Oct 25;38(986):95-6 | Show Full Introduction Hide Full Introduction

Terbinafine for Onychomycosis

The Medical Letter on Drugs and Therapeutics • August 16, 1996; (Issue 981)

Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment...

Terbinafine (Lamisil - Sandoz), an allylamine synthetic antifungal, previously available in the USA in a topical formulation (Medical Letter, 35:76, 1993) has now been marketed for oral use in the treatment of fungal nail infections caused by dermatophytes. Oral terbinafine has been available in Europe since 1992.

Med Lett Drugs Ther. 1996 Aug 16;38(981):72-4 | Show Full Introduction Hide Full Introduction

Choice of Lipid-Lowering Drugs

The Medical Letter on Drugs and Therapeutics • August 2, 1996; (Issue 980)

Drugs that lower elevated plasma cholesterol concentrations can prevent formation, slow progression and cause regression of atherosclerotic lesions, and may also improve coronary vasodilatation (JW Jukema et al, circulation, 91:2528, 1995: CB Treasure er al, N Engl J Med, 332:481, 1995; TJ Anderson et al, N Engl J Med, 332:488, 1995). All these drugs must be continued indefinitely; when htey are stopped, plasma cholesterol concentrations generally return to pretreatment levels.

Med Lett Drugs Ther. 1996 Aug 2;38(980):67-70 | Show Full Introduction Hide Full Introduction

Systemic Antifungal Drugs

The Medical Letter on Drugs and Therapeutics • February 2, 1996; (Issue 967)

The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug...

The drugs of choice for treatment of deep fungal infections are listed in the table on page 101. Some of the indications and dosages recommended here have not been approved by the US Food and Drug Administration. More detailed guidelines are available from the Infectious Diseases Society of America (J Sobel et al, Clin Infect Dis, volume 30, April 2000).

Med Lett Drugs Ther. 1996 Feb 2;38(967):10-2 | Show Full Introduction Hide Full Introduction

Itraconazole for Onychomycosis

The Medical Letter on Drugs and Therapeutics • January 19, 1996; (Issue 966)

Itraconazole (Sporanox - Janssen), an oral antifungal triazole that has been available in the USA since 1992 for treatment of deep fungal infections (Medical Letter, 35:7, 1993), is now being marketed for treatment of dermatophyte infections of the toenails, with or without fingernail involvement.

Med Lett Drugs Ther. 1996 Jan 19;38(966):5-6 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated Infections

The Medical Letter on Drugs and Therapeutics • October 13, 1995; (Issue 959)

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with...

Results of recently completed clinical trials have led to some changes in recommendation for treatment of human immunodeficiency virus (HIV) and other infections associated with AIDS.

Med Lett Drugs Ther. 1995 Oct 13;37(959):87-94 | Show Full Introduction Hide Full Introduction

Drugs For Tuberculosis

The Medical Letter on Drugs and Therapeutics • August 4, 1995; (Issue 954)

Tuberculosis (TB) continues to be a major problem in the United States, particularly in areas where drug resistance is common (Morbid Mortal Weekly Rep, 44:387, May 26, 1995). Since poor compliance is the most important cause of treatment failure and is associated with emergence of drug resistence, some experts now recommend that all patients take drugs for TB under direct observation (SE Weis et al, N Engl J Med, 330:1179, 1994; R Bayer and D Wilkinson, Lancet, 345:1545, June 17, 1995).

Med Lett Drugs Ther. 1995 Aug 4;37(954):67-70 | Show Full Introduction Hide Full Introduction

Drugs for Tuberculosis

The Medical Letter on Drugs and Therapeutics • October 29, 1993; (Issue 908)

The rising incidence of tuberculosis (TB) has been accompanied by a dramatic increase in drug resistance in some areas of the USA (TR Frieden et al, N Engl J Med, 328:521, 1993). Since poor compliance is the most important cause of treatment failure and associated with emergence of drug resistance, some experts now recommend that patients with TB take their drugs under direct obeservation (MD Iseman et al, N Engl J Med, 329:576, 1993).

Med Lett Drugs Ther. 1993 Oct 29;35(908):99-102 | Show Full Introduction Hide Full Introduction

Drugs for AIDS and Associated infections

The Medical Letter on Drugs and Therapeutics • September 3, 1993; (Issue 904)

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with...

Results of recently completed clinical trials have led to some changes in recommendations for treatment of human immunodeficiency virus (HIV) and other infections associted with AIDS.

Med Lett Drugs Ther. 1993 Sep 3;35(904):79-86 | Show Full Introduction Hide Full Introduction

Topical Terbinafine for Tinea Infections

The Medical Letter on Drugs and Therapeutics • August 20, 1993; (Issue 903)

Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of...

Terbinafine 1% cream (Lamisil - Sandoz), an allylamine synthetic antifungal drug chemically related to naftifine (Naftin - Medical Letter, 30:98, 1988), is now available in the USA for topical treatment of tinea pedis, tinea cruris, and tinea corporis infections. An oral formulation is available in Europe and is under investigation here.

Med Lett Drugs Ther. 1993 Aug 20;35(903):76-8 | Show Full Introduction Hide Full Introduction

The Medical Letter on Drugs and Therapeutics • January 22, 1993; (Issue 888)

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses...

Itraconazole (Sporanox - Janssen), an antifungal triazole, has been approved by the US Food and Drug Administration (FDA) for oral treatment of histoplasmosis and blastomycosis. These two endemic mycoses occur both in normal hosts and in immunocompromised patients, such as those with AIDS (RW Bradsher, Clin Infect Dis, 14:S82, 1992; LJ Wheat, Clin Infect Dis, 14:S91, 1992).

Med Lett Drugs Ther. 1993 Jan 22;35(888):7-9 | Show Full Introduction Hide Full Introduction

New Advertisement for An Old Antihistamine

The Medical Letter on Drugs and Therapeutics • January 22, 1993; (Issue 888)

Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24,...

Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.

Med Lett Drugs Ther. 1993 Jan 22;35(888):9-10 | Show Full Introduction Hide Full Introduction

Drugs For Treatment Of Fungal Infections

The Medical Letter on Drugs and Therapeutics • February 21, 1992; (Issue 864)

The incidence of opportunistic fungal infections continues to increase, particularly in patients who have AIDS, are taking immunosuppressive drugs, or are in intensive care units. Intravenous (IV) amphotericin B (Fungizone, and others), sometimes given with flucytosine (Ancobon), is the drug of choice for initial treatment of most rapidly progressive, acutely life-threatening fungal infections; for less severe infections, fluconazole (Diflucan, ketoconazole (Nizoral), or itraconazole (Sporanox - an investigational drug in the (USA) may also be effective, can be taken orally, and are much better tolerated. The treatment of superficial fungal infections is not discussed here.

Med Lett Drugs Ther. 1992 Feb 21;34(864):14-6 | Show Full Introduction Hide Full Introduction

Drugs For AIDS And Associated Infections

The Medical Letter on Drugs and Therapeutics • October 18, 1991; (Issue 855)

A growing number of clinical trials now permits some consensus on the treatment of human immunodeficiency virus (HIV) and other infections associated with acquired immune deficiency syndrome (AIDS) in...

Med Lett Drugs Ther. 1991 Oct 18;33(855):95-102 | Show Full Introduction Hide Full Introduction